Clinical pharmacokinetics of lorazepam. IV. Long-term oral administration.
Fifteen healthy male volunteers received long-term daily treatment with oral lorazepam at doses as high as 10 mg per day for a period of 26 weeks. Steady-state plasma concentrations of lorazepam and its glucuronide metabolite were measured in all subjects at least every two weeks. At daily doses of 6 mg per day, the mean steady-state lorazepam level was 88 ng/ml and that of lorazepam glucuronide was 170 ng/ml. Mean levels among seven subjects who received 10 mg per day were 164 and 266 ng/ml, respectively. Lorazepam concentrations fluctuated from week to week despite constant dosage, but there was no evidence of systematic variation. Mean steady-state lorazepam levels were highly correlated with daily dose in mg/kg, but were not related to age. Lorazepam was not detected in any plasma samples drawn one week after discontinuation of treatment.
D000284:Administration, Oral; D000328:Adult; D000367:Age Factors; D014151:Anti-Anxiety Agents / Q000097:blood*; D005965:Glucuronates / Q000097:blood; D006801:Humans; D007700:Kinetics; D008140:Lorazepam / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D014151:Anti-Anxiety Agents; D005965:Glucuronates; D008140:Lorazepam